Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salivary gland botulinum toxin injection to prevent ventilator-associated pneumonia in critically ill neurological patients
ChiCTR2500107872Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of neuronox in ventilator-associated pneumonia (VAP) and neurological diseases (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Incidence of ventilator-associated pneumonia. Started Aug 2025; status: recruiting.
02
Drugs
neuronox
03
Conditions
ventilator-associated pneumonia (VAP)neurological diseases
Beyond the preview
Go deeper on ChiCTR2500107872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107872.